Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges
Authors
Keywords
Inflammatory myofibroblastic tumor, rare tumor, pediatrics, molecular profiling, targeted therapy, crizotinib, ALK inhibition
Journal
CURRENT PROBLEMS IN CANCER
Volume 45, Issue 4, Pages 100768
Publisher
Elsevier BV
Online
2021-07-01
DOI
10.1016/j.currproblcancer.2021.100768
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG)
- (2020) Michela Casanova et al. EUROPEAN JOURNAL OF CANCER
- Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors
- (2020) Elena V. Preobrazhenskaya et al. PEDIATRIC BLOOD & CANCER
- Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK).
- (2020) Johannes H Schulte et al. JOURNAL OF CLINICAL ONCOLOGY
- CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma
- (2020) Ashleigh M. Fordham et al. BRITISH JOURNAL OF CANCER
- The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis
- (2020) Giacomo Giulio Baldi et al. ONCOLOGIST
- Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib
- (2020) Han Hsi Wong et al. ANTI-CANCER DRUGS
- ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects
- (2019) Erica Brivio et al. PEDIATRIC BLOOD & CANCER
- Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1–ALK fusion: a case report
- (2019) Kazunori Honda et al. INVESTIGATIONAL NEW DRUGS
- Gene fusion involving the insulin-like growth factor 1 receptor in an ALK-negative inflammatory myofibroblastic tumour
- (2019) Giuseppe Piarulli et al. HISTOPATHOLOGY
- Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance
- (2019) Jon Zugazagoitia et al. LUNG CANCER
- PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
- (2019) A. Drilon et al. Journal of Thoracic Oncology
- How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature
- (2019) Ozkan Alan et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer
- (2019) Maurice Pérol et al. LUNG CANCER
- Inflammatory Myofibroblastic Tumor Driven by Novel NUMA1-ALK Fusion Responds to ALK Inhibition
- (2018) Nisha Rao et al. Journal of the National Comprehensive Cancer Network
- PD-L1 expression in inflammatory myofibroblastic tumors
- (2018) Tricia R Cottrell et al. MODERN PATHOLOGY
- ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties
- (2018) Merrida A Childress et al. MOLECULAR CANCER RESEARCH
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inflammatory myofibroblastic tumors-A retrospective analysis of the Cooperative Weichteilsarkom Studiengruppe
- (2018) Stefanie Kube et al. PEDIATRIC BLOOD & CANCER
- Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial
- (2018) Patrick Schöffski et al. Lancet Respiratory Medicine
- Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
- (2018) Dazhi Liu et al. Therapeutics and Clinical Risk Management
- A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma
- (2018) Barbara M Parker et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements
- (2018) Jason C. Chang et al. Journal of Thoracic Oncology
- Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene
- (2017) Masafumi Saiki et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study
- (2017) Yael P. Mossé et al. JOURNAL OF CLINICAL ONCOLOGY
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma
- (2017) Quan Jiang et al. Orphanet Journal of Rare Diseases
- Crizotinib in ALK+ inflammatory myofibroblastic tumors-Current experience and future perspectives
- (2017) Till-Martin Theilen et al. PEDIATRIC BLOOD & CANCER
- Identification of NTRK fusions in pediatric mesenchymal tumors
- (2017) Dean Pavlick et al. PEDIATRIC BLOOD & CANCER
- PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors
- (2017) Yoon Jin Cha et al. Oncotarget
- ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors
- (2016) Ali H. Alassiri et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- ChromoplecticTPM3–ALKrearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib
- (2016) A. S. Mansfield et al. ANNALS OF ONCOLOGY
- MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research
- (2016) W. Chang et al. CLINICAL CANCER RESEARCH
- ALK,ROS1andNTRK3gene rearrangements in inflammatory myofibroblastic tumours
- (2016) Hidetaka Yamamoto et al. HISTOPATHOLOGY
- ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma
- (2016) Jen-Chieh Lee et al. JOURNAL OF PATHOLOGY
- Aggressive Metastatic Inflammatory Myofibroblastic Tumor After Allogeneic Stem Cell Transplant With Fatal Pulmonary Toxicity From Crizotinib
- (2016) Hwazen Shash et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity
- (2016) Akira Ono et al. LUNG CANCER
- Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib
- (2016) Carlo Gambacorti-Passerini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Characterization of Inflammatory Myofibroblastic Tumors With Frequent ALK and ROS1 Gene Fusions and Rare Novel RET Rearrangement
- (2015) Cristina R. Antonescu et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors
- (2015) Jason L Hornick et al. MODERN PATHOLOGY
- Tumor inflamatorio miofibroblástico peritoneal. Respuesta favorable asociada a infliximab: Caso clínico
- (2015) Daniela Grünholz et al. REVISTA MEDICA DE CHILE
- Adult-onset inflammatory myofibroblastic tumour of the stomach with aTFG-ROS1fusion
- (2014) Hiromi Fujita et al. HISTOPATHOLOGY
- Intra-abdominal inflammatory myofibroblastic tumor: Spontaneous regression
- (2014) Jun-Jie Zhao WORLD JOURNAL OF GASTROENTEROLOGY
- Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
- (2014) C. M. Lovly et al. Cancer Discovery
- Inflammatory Myofibroblastic Tumors in Childhood
- (2013) Bhakti Mehta et al. PEDIATRIC HEMATOLOGY AND ONCOLOGY
- Corticosteroids may favor proliferation of thoracic inflammatory myofibroblastic tumors
- (2013) Serena Panigada et al. PEDIATRIC PULMONOLOGY
- Fusion of dynactin 1 to anaplastic lymphoma kinase in inflammatory myofibroblastic tumor
- (2012) Xiaoke Wang et al. HUMAN PATHOLOGY
- Fibroblastic and Myofibroblastic Tumors in Children and Adolescents
- (2012) Cheryl M. Coffin et al. PEDIATRIC AND DEVELOPMENTAL PATHOLOGY
- Epithelioid Inflammatory Myofibroblastic Sarcoma
- (2010) Adrián Mariño-Enríquez et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
- (2010) T. Sasaki et al. CANCER RESEARCH
- Letter to the Editor
- (2010) Maurizia Colangelo et al. JOURNAL OF PEDIATRIC SURGERY
- Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
- (2010) James E. Butrynski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
- (2009) Thomas R Webb et al. Expert Review of Anticancer Therapy
- An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features
- (2008) Sung-Ting Chen et al. HUMAN PATHOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started